David Epstein Sells 370 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $90.00, for a total transaction of $33,300.00. Following the completion of the transaction, the director owned 26,671 shares of the company’s stock, valued at $2,400,390. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $72.09 on Friday. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $104.32. The stock has a market capitalization of $12.52 billion, a P/E ratio of -60.58 and a beta of 4.86. The company’s 50-day moving average is $85.99 and its 200 day moving average is $70.61. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 1.43.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The business had revenue of $334.21 million for the quarter, compared to analysts’ expectations of $328.89 million. During the same period in the previous year, the firm posted ($0.46) EPS. The business’s revenue was up 84.7% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Hedge Funds Weigh In On Tempus AI

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Tempus AI by 6,247.5% during the 1st quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company’s stock valued at $289,204,000 after buying an additional 5,900,668 shares in the last quarter. ARK Investment Management LLC grew its position in shares of Tempus AI by 35.9% during the first quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company’s stock worth $361,867,000 after purchasing an additional 1,981,755 shares in the last quarter. Nikko Asset Management Americas Inc. raised its stake in Tempus AI by 31.5% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company’s stock valued at $205,401,000 after purchasing an additional 1,021,460 shares during the period. AQR Capital Management LLC bought a new stake in Tempus AI during the 2nd quarter valued at approximately $54,020,000. Finally, CloudAlpha Capital Management Limited Hong Kong purchased a new position in Tempus AI in the 1st quarter worth approximately $34,119,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Morgan Stanley upped their price target on Tempus AI from $65.00 to $68.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 12th. Cowen cut shares of Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Piper Sandler raised their price target on Tempus AI from $70.00 to $105.00 and gave the company a “neutral” rating in a report on Wednesday, October 22nd. BTIG Research restated a “buy” rating and issued a $96.00 price objective on shares of Tempus AI in a report on Wednesday. Finally, TD Cowen cut shares of Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 target price on the stock. in a research note on Tuesday, October 21st. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $80.54.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.